Iterum Therapeutics plc (ITRMF) Share-based Compensation (2017 - 2025)

Iterum Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $238000.0 for Q3 2025.

• In Q3 2025, Share-based Compensation fell 34.62% year-over-year to $238000.0; the TTM figure through Sep 2025 stood at $238000.0 (down 34.62% YoY), while the FY2024 annual figure was $363000.0, down 67.47% from the prior year.
• Share-based Compensation for Q3 2025 stood at $238000.0, up from $127000.0 in the prior quarter.
• The five-year high for Share-based Compensation was $2.6 million in Q1 2021, with the low at $44000.0 in Q2 2023.
• The 5-year median for Share-based Compensation is $364000.0 (2024), against an average of $695368.4.
• The sharpest annual moves came in 2021 and 2023: Share-based Compensation surged 1461.11% in 2021, then sank 92.83% in 2023.
• Iterum Therapeutics' Share-based Compensation stood at $2.0 million in 2021, then sank by 76.77% to $457000.0 in 2022, then tumbled by 69.58% to $139000.0 in 2023, then slumped by 35.97% to $89000.0 in 2024, then surged by 167.42% to $238000.0 in 2025.
• Business Quant data shows ITRMF's Share-based Compensation at $238000.0 in Q3 2025, $127000.0 in Q2 2025, and $203000.0 in Q1 2025.